Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cipla Takes To Future Therapies With Stempeutics Pact; Says Preparing For The Big Changes In Research

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Future sciences like monoclonal antibodies or stem cell therapies are not just attracting the fancy of multinational companies scrambling to expand their pipelines; even generic drug makers like India's Cipla are getting drawn into start-up companies and demonstrating an ability to bring to market products that can potentially revolutionalize treatment regimens

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts